Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S006 8/6/03 8/15/03 8/15/03 Relenza (zanamivir for inhalation), GlaxoSmithKline 21-036/S005 8/5/03 8/15/03 8/6/03 Relenza (zanamivir for inhalation), 5 mg, Glaxo Wellcome, 21-036/S004 4/27/01 05/08/03 Relenza (zanamivir for inhalation),5 mg, Patient Label Glaxo Wellcome, 21-036/S001 4/26/00 4/27/00 4/27/00 Relenza (zanamivir for inhalation) GlaxoWellcome NDA 21-036 7/26/99 12/30/99 7/27/99 12/27/99 Relenza Indication: For the treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days. | RELENZA (zanamivir) inhalation, GlaxoSmithKline, New or Modified Indication | RELENZA (zanamivir) Inhalation, GlaxoSmithKline, Labeling Revision Check the most up-to-date list of FDA Approvals.                                                                                      A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2009 Betterchem.com